Skip to main content

Table 4 Immunological and virological parameters at baseline in ISS T-002 and ISS OBS T-002 study participants

From: HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial

 

ISS T-002

ISS OBS T-002

p-value b

 

n

Mean ± s.d. a

n

Mean ± s.d. a

 

Phenotype (cells/μL)

     

CD4+

152

661 ± 231

79

700 ± 300

0.2671

CD8+

152

802 ± 393

79

881 ± 360

0.1295

B

152

241 ± 121

79

307 ± 164

0.0006

NK

152

232 ± 152

79

268 ± 193

0.1231

CD4 + subsets (%)

     

Naïve

94

31 ± 14

31

28 ± 13

0.7057

Effector memory

94

22 ± 12

31

20 ± 8

0.5304

Central memory

94

47 ± 10

31

51 ± 9

0.2810

CD8 + subsets (%)

     

Naïve

94

26 ± 11

31

30 ± 11

0.0835

Effector memory

94

52 ± 13

31

47 ± 13

0.0756

Central memory

94

22 ± 10

31

23 ± 9

0.7302

HIV DNA (log 10 copies/10 6 CD4 + cells)

142

3.1 ± 0.5

54

3.0 ± 0.5

0.4381

Tat 7.5 μg, 3x

36

3.1 ± 0.6

   

Tat 7.5 μg, 5x

36

3.0 ± 0.6

   

Tat 30 μg, 3x

36

3.2 ± 0.5

   

Tat 30 μg, 5x

34

3.0 ± 0.5

   
  1. "n indicates the number of individuals evaluable for each parameter according to residual specimen availability, since they were part of second line laboratory testing".
  2. aStandard deviation; b t-test was applied.